#7 Biogen Idec
Ticker: BIIB
YTD performance: 41%
Market cap: $22.8 billion

Biogen Idec (BIIB), a maker of specialized treatments for neurological diseases like multiple sclerosis, benefited from two positive developments in its drug pipeline this year.

In April, the company announced positive results from a Phase 3 clinical trial for a new MS treatment called BG-12. Phase 3 trials are often the last step in a drug's development before it heads to market.

Later that month, the Food and Drug Administration approved the drug Rituxan, which Biogen co-developed with Roche's (RHBBY) Genentech, for use in treating two extremely rare diseases -- Wegener's Granulomatosis and Microscopic Polyangiitis.The combination of those two events sent shares of Biogen up more than 30% in April alone.




All data current as of June 17, 2011.
Last updated June 29 2011: 7:39 AM ET
Join the Conversation

The market has had its struggles in the first half of the year, but these 10 stocks are really making a stink. From RadioShack to AIG, here are the biggest losers so far in 2011. More

The Federal Reserve's $600 billion bond buying stimulus is winding down, and experts say stocks don't need anything more. More